German biotechnology firm TQ Therapeutics GmbH has strategically acquired Juno Therapeutics GmbH, dramatically expanding capabilities for developing next-generation ultra-short extracorporeal cell and gene therapy systems that could transform patient access to personalised cellular treatments.

Key technical innovations driving platform development

TQ Therapeutics (TQx) completed acquisition of Juno Therapeutics GmbH, Bristol Myers Squibb’s German subsidiary, through an undisclosed transaction that positions the Martinsried-based company at the forefront of automated cellular therapy production. This strategic consolidation accelerates development of TQx’s decentralised processing platform, which employs advanced automation technologies including nanoscale cell manipulation systems, enhanced scalability protocols, and dramatically reduced manufacturing timeframes compared to traditional centralised production methods.

The acquisition grants TQx access to critical intellectual property portfolios encompassing automated cell processing technologies, established licensing frameworks for therapeutic development, and advanced extracorporeal therapy protocols essential for their transformative platform.

Implications for therapeutic accessibility

“This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future,” said Dr Christian Eckert, TQx chief executive officer. “This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients.”

This integration represents a critical advancement towards realising automated, point-of-care cellular therapy production with unprecedented accessibility potential.